Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient.

Beatriz Somoza-FernándezVicente Escudero-Vilaplana Roberto Collado-BorrellSara Pérez-RamírezCristina Villanueva-BuenoMaría Del Pilar Montero-AntónAna Herranz-AlonsoMaría Sanjurjo-Saez

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)

There is scarce evidence in the literature concerning androgen receptor pathway inhibitor-related neutropenia. However, its life-threatening potential cannot be ignored, so healthcare professionals should be warned of the possibility of the occurrence of such adverse reactions.

Keyphrases

prostate cancer
radical prostatectomy
chemotherapy induced
risk assessment
systematic review
case report
early onset
human health